MHRA updates finasteride and dutasteride warnings
If you have seen headlines about finasteride and dutasteride, the first thing to know is that the MHRA has not banned these medicines. It has strengthened safety warnings, which is different. In plain terms, the UK regulator is telling doctors, pharmacists and patients to talk more clearly about possible risks that some people may face while taking them. According to the MHRA, finasteride is used at 1mg for male pattern hair loss and at 5mg for benign prostatic hyperplasia, which means an enlarged prostate. Dutasteride 0.5mg is also used for benign prostatic hyperplasia. **What this means:** this update matters both to people using a hair-loss treatment and to people taking prostate medicines.
The most specific change in the product information is for finasteride 1mg, the version used for androgenetic alopecia, another term for male pattern hair loss. In its Drug Safety Update, the MHRA says the wording will now make clearer that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has been reported both with and without mood changes. A precautionary warning is also being added to the product information for dutasteride. The MHRA says mood alterations have been reported with finasteride, which is in the same class of medicines, so the dutasteride advice is being updated to reflect that related concern. This round of product information changes applies to finasteride 1mg and dutasteride 0.5mg medicines. **What to notice here:** regulators are not saying the two medicines are identical, but they are telling patients and prescribers not to ignore warnings seen within the same family of drugs.
This is a useful example of how drug safety reviews usually work. A medicine can stay on the market while the warnings around it change, because regulators are constantly weighing benefit against risk rather than making a simple safe-or-unsafe judgement. The MHRA says this latest step followed an additional review of the evidence, including the outcome of a European regulatory review and expert advice from the Commission on Human Medicines. **Why that matters:** safety wording is not changed on a whim. Reports are gathered, experts assess patterns, and official guidance is updated when the case for clearer warnings becomes strong enough.
For patients, the advice is practical rather than abstract. The MHRA says anyone taking finasteride who experiences depression or suicidal thoughts should stop treatment and seek medical advice. If you are worried about sexual side effects, the advice is to speak to a healthcare professional rather than silently putting up with symptoms or guessing your way through them. Existing UK patient alert cards for finasteride, introduced in 2024, remain in place. Those cards warn about sexual dysfunction, depression and suicidal thoughts, and they tell patients what action to take if side effects occur. If you are prescribed finasteride, this is exactly the sort of information you should expect to be talked through.
Dr Alison Cave, the MHRA’s Chief Safety Officer, said the aim is to support informed decisions between prescribers and patients. That phrase can sound dry, but it points to something important: consent in medicine only works properly when you are told the likely benefits, the known risks and the warning signs that should send you back for help. The MHRA is also asking patients and healthcare professionals to report suspected side effects through the Yellow Card scheme. **Think of this as the public evidence line for medicines:** one report does not prove a drug caused a problem, but patterns in reports can help regulators spot risks earlier and sharpen the advice that appears in leaflets, labels and consultations.
The wider lesson is not to read a safety update as a reason for instant panic, and not to brush it off either. A warning update means the regulator thinks the information around a medicine needs to be clearer, so that treatment choices are made with open eyes. If you take finasteride or dutasteride, the next sensible step is a calm one: check which medicine and dose you are on, read the latest patient information, and bring any concerns to your GP, specialist or pharmacist. The MHRA’s job is to regulate medicines and medical devices by judging whether their benefits justify their risks. This update is part of that work, and for patients the main message is simple: ask questions, notice changes, and report side effects when they happen.